A report this week in Urologic Oncology has confirmed the importance of PSA doubling times in understanding risk for prostate cancer progression among men with non-metastatic, castration-resistant prostate cancer (nmCRPC). The paper by Freedland et al. in Urologic Oncology reviewed data from just over 12,000 men with nmCRPC being treated within the Veterans Administration health […]
↧